Stay updated with breaking news from Acelyrin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The biggest biotech financing of the past week belongs to a startup developing an immunology drug that could rival blockbuster products sold by big pharmaceutical companies. Cell therapy, cancer, and rare disease also figured into this week’s startup cash hauls.
Financing to fund izokibep Phase 3 development in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) through anticipated submission of biologic...
/PRNewswire/ -- ACELYRIN, INC. today announced the appointment of Gil M. Labrucherie as Chief Financial Officer effective July 18. Labrucherie will report to...
/PRNewswire/ -- ACELYRIN, INC., an innovative clinical-stage biopharma company that identifies, acquires, and accelerates the development and commercialization...
/PRNewswire/ -- ACELYRIN, INC., an innovative clinical-stage biopharma company that identifies, acquires, and accelerates the development and commercialization...